52 minutes ago
19
A drug that was conceived by artificial intelligence, designed in roughly 18 months, and showed striking improvements in lung function is now in its final stretch of human testing. Insilico Medicine’s rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 patients enrolled.
The stakes are unusually high. Rentosertib isn’t just targeting idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease with limited treatment options. Its mechanism of action goes after cellular senescence itself, the biological process underpinning much of what we call aging.
The numbers that got everyone’s attention
Phase IIa results, published in Nature Medicine in June 2025, told a compelling story. Patients receiving the 60 mg dose of rentosertib saw a mean increase of 98.4 mL in forced vital capacity (FVC) over 12 weeks. The placebo group, by contrast, experienced a decrease of 20.3 mL.
The drug also demonstrated what researchers described as a manageable safety profile. In a disease space where existing therapies like nintedanib and pirfenidone merely slow decline and come with significant side effects, a treatment that actually improves lung function while remaining tolerable would represent a genuine paradigm shift.
How AI built a drug in 18 months
Rentosertib’s origin story reads like a proof of concept for the entire AI drug discovery movement. Insilico Medicine used its proprietary platforms, PandaOmics for target identification and Chemistry42 for molecular design, to identify TNIK (TRAF2- and NCK-interacting kinase) as a novel target and then generate a drug candidate to hit it.
TNIK sits at the intersection of several signaling pathways implicated in fibrosis, including TGF-β and Wnt. But what makes the target particularly interesting is its role in the senescence-associated secretory phenotype (SASP), the cocktail of inflammatory signals that aging cells pump out to damage their neighbors. Preclinical studies showed rentosertib has senomorphic properties, meaning it doesn’t kill senescent cells outright but modulates their harmful signaling.
Phase III design and what’s ahead
The Phase III trial is structured as a randomized, double-blind, placebo-controlled study. Key investigators include Zuojun Xu, Nanshan Zhong (one of China’s most prominent respiratory medicine specialists, known globally for his role during the SARS outbreak), and Chang Chen.
Insilico Medicine itself appears to be in solid financial shape to see this through. The company reported a positive profit forecast for the first half of 2026, citing pipeline advancements including rentosertib as key drivers.
Why this matters beyond one drug
The longevity angle adds another dimension entirely. Cellular senescence is implicated in dozens of age-related diseases, from neurodegeneration to cardiovascular disease to cancer. Insilico has been transparent about viewing rentosertib’s mechanism through an aging biology lens, not just a fibrosis one.
The Phase III trial is expected to take several years to read out, as is typical for chronic disease studies. But the data collected along the way, including biomarker analysis of SASP factors and senescence markers, could provide some of the most detailed human evidence yet on whether pharmacologically targeting the biology of aging is feasible.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
English (US) ·